China’s National Medical Products Administration (NMPA) issued a sweeping new policy to encourage the innovation and international competitiveness of high-end medical devices. Published in July 2025, the “Announcement on Optimizing Whole-Life-Cycle Regulation to Support Innovative Development of High-End Medical Devices” specifies ten strategic measures to facilitate regulatory efficiency and encourage innovation in technologies such as AI-based diagnosis, surgical robots, and imaging equipment.
The major aspects of the policy include advanced product classification systems adapted to new technologies, increased development and publishing of standards, streamlined approval procedures, improved post-market regulation, and proactive quality and safety monitoring.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.